Abstract: A tiered therapeutic reservoir of an ophthalmic device is described for controlled delivery of two or more therapeutic doses to a patient's eye. An ophthalmic device can include a reservoir having an interior and a metal electrode covering an opening of the reservoir. The interior of the reservoir can hold one or more pharmaceuticals or does of pharmaceuticals (referred to as drugs). The reservoir can hold a first drug and a second drug, with a sacrificial barrier layer positioned between the first drug and the second drug. The metal electrode can electrodissolve upon receiving an electrical signal to release the first drug from the reservoir. The sacrificial barrier layer can be sacrificed after the electrodissolution of the metal electrode to release the second drug from the reservoir. The first drug and the second drug can be released to an eye of a patient in contact with the ophthalmic device.

Abstract: Disclosed herein are pharmaceutical compositions in the form of a suspension for oral delivery. Some embodiments provide a pharmaceutical composition in the form of a suspension for oral delivery comprising an active pharmaceutical ingredient; water; a suspending agent; a buffering agent; and one or more of a wetting agent and a binder/filler. In some embodiments, the active pharmaceutical ingredient is selected from quetiapine, sildenafil, tadalafil, cinacalcet, ticagrelor, mycophenolate, aprepitant, zonisamide, and primidone.

Abstract: The present disclosure relates to chewable gel products containing a gel carrier and an active pharmaceutical ingredient (API), where the chewable gel product has an acceptable taste.

Abstract: A method of introducing a physiologically-active agent into the circulatory system of a mammal is disclosed herein. The method utilizes a rapid drug delivery system which prevents deactivation or degradation of the active agent being administered to a patient in need of treatment. In particular, the drug delivery system is designed for pulmonary drug delivery such as by inhalation, for delivery of the active agents such as proteins and peptides to the pulmonary circulation in a therapeutically effective manner avoiding degradation of the active agents in peripheral and vascular tissue before reaching the target site.

Abstract: The present disclosure relates to inhalable dry powder formulations comprising one or more antibodies or one or more angiogenesis inhibiting active pharmaceutical ingredients, methods of manufacture of such compositions, e.g., via spray drying, as well as their local administration to the lung for use in the treatment, prevention and/or delay of progression of asthma, COPD, lung infections, cystic fibrosis, or lung cancer.

Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

Abstract: The present invention relates, in various embodiments, to formulations comprising hydrocortisone and silicon dioxide. In additional embodiments, the invention relates to suppositories comprising hydrocortisone and silicon dioxide. The formulations of the present invention are useful for administration to patients who have gastrointestinal diseases and disorders such as, for example, inflammatory bowel disease.

Abstract: The present invention provides for an oral solution that includes atomoxetine, or pharmaceutically acceptable salt thereof, methods of manufacturing the oral solution, and methods of treating attention deficit hyperactivity disorder (ADHD) in a human subject that include orally administering the oral solution to a human subject in need thereof.

Abstract: The disclosure herein describes solubilizing an ibuprofen in water forming a complex with a hydrotrope and controlling the pH of the water or water-based solution. The methods for solubilizing ibuprofen in water are described. These methods can include forming a colloidal suspension of the ibuprofen, and then forming an aqueous colloidal suspension from the colloidal suspension.

Abstract: A novel PEGylated lipid and preparation methods thereof, a cationic liposome containing the PEGylated lipid, a pharmaceutical composition containing the liposome, a formulation and application thereof. The PEGylated lipid can be used for modifying a liposome, and it can be further modified and coupled with a targeting group, and then used for modifying a liposome to obtain a liposome with the targeting group. Due to the presence of a long-chain PEG and the targeting group on the lipid, the modified liposome can avoid being removed by the reticuloendothelial system in a human body and realize a targeting function. Therefore, when the modified liposome delivers an active drug to cells or a patient, especially when delivering a nucleic acid or anti-tumor drug, the liposome can realize long circulation in vivo and improve the transport efficiency of drug, and has a targeting unction so the therapeutic effect of a drug is improved.

Abstract: The present invention relates to polymer nanodiscs comprising a lipid bilayer and an amphiphilic polymer, and to a pharmaceutical composition comprising the polymer nanodiscs. The polymer nanodiscs of the present invention, comprising the lipid bilayer and the amphiphilic polymer, exhibit an antivirus effect when used, and thus may be used for preventing or treating virus infections.

Abstract: The present disclosure relates to the composition and methods of manufacturing and use of dissociating polymeric matrix oral dosages (disintegrating pre-formed oral dosage hydrogels) loaded with fulvestrant as an orally delivered therapy for the treatment of diseases, particularly cancer and especially metastatic breast cancer.

Abstract: The instant disclosure relates to nucleic acid-lipid particles that mix ionizable and cationic lipids, which preferentially localize and deliver associated cargoes to the liver when administered parenterally, and which optionally can be used to deliver associated cargoes to tissues to which such particles are directly injected. The instant disclosure provides compositions comprising such lipid particles, optionally in association with a therapeutic agent (e.g., a therapeutic mRNA and/or nucleic acid controller system), as well as methods and kits for delivering a lipid particle-associated therapeutic agent and/or treating a disease or disorder, e.g., a liver disease or disorder, in a subject, using the lipid particle compositions provided herein.

Abstract: The present invention relates to drug-delivery compositions comprising microparticles with the shape of a prism comprising at least one polymer and at least one CCR2 inhibitor. Preferably said composition is for the treatment of local chronic inflammation diseases, such as osteoarthritis.

Abstract: Provided herein are methods of treatment, compositions, systems and kits using polymer particles as restraints of neutrophil function. Such methods include, but are not limited to, methods of preventing, treating, and/or ameliorating inflammatory diseases, infections, autoimmune diseases, malignant diseases, and other diseases or conditions in which neutrophils may be implicated. In some embodiments, polymer particles are useful for diagnosing neutrophil related diseases or conditions.

Abstract: A capsule for specific drug delivery and a preparation method therefor, relating to a capsule containing a non-liquid filler and a modified release coating. The modified release coating covers a capsule shell, an isolating layer is provided between the capsule shell and the modified release coating, and no sealing film is provided between the body and cap of the capsule. The capsule can be used for delivering a drug to an intestinal track, and exhibits excellent characteristics in mass production of capsules and drug release.

Abstract: The present disclosure describes, in part, exosomes comprising miRNA for the reprogramming of fibroblasts and methods of using the same.

Abstract: Described herein are compositions, kits, and methods for potent systemic delivery to a cell of a subject. Also described herein are pharmaceutical compositions comprising a therapeutic or prophylactic agent assembled to a lipid composition. The lipid composition can comprise an ionizable cationic lipid, a phospholipid, and a selective organ targeting lipid. Further described herein are high-potency dosage forms of a therapeutic or prophylactic agent formulated with a lipid composition.

Abstract: This invention provides polymeric nanoparticles presenting non-conjugated BBB-crossing ligands on their surfaces, compositions and methods of use thereof, as well as non-conjugation methods to produce nanoparticles having BBB-crossing agents on their surfaces.

Abstract: A drug delivery system for oral administration is provided. The drug delivery system includes an oral delivery carrier and a plurality of micelles attached to or dispersed in the oral delivery carrier. Each of the micelles includes a hydrophobic core and a hydrophilic corona targeted to a subject's kidney. A pharmaceutical payload is carried by the plurality of micelles. Another drug delivery system includes a plurality of micelles and a payload within each micelle. Each micelle has a kidney targeting peptide conjugated thereto with a polyethylene glycol linking group having a molecular weight less than 1800 Daltons.

Abstract: In this specification, an expandable structured dosage form for prolonged drug delivery is disclosed. The dosage form comprises a three-dimensional structural framework of physiological fluid-absorptive, drug-containing elements surrounded by interconnected free space. Upon immersing in a physiological fluid, the fluid percolates interconnected free space between elements, and the three-dimensional structural framework expands with fluid absorption and releases drug overtime. The disclosed dosage form enables prolonged delivery of drug into the upper gastrointestinal tract and the blood at a controlled rate for improving the efficacy and safety of drug therapies.

Abstract: Methods of producing a Hydrophilic Homeopathic Aqueous Substance Active (HASA)-gel matrix, include the steps of: (a) combining a homeopathic compound and an uninhibited aqueous composition to produce a HASA; (b) combining the HASA with at least one hydrophilic gelling agent; and (c) thereafter, forming the hydrophilic HASA-gel matrix by use of at least one of a thickening agent, a crosslinking agent, or a polymerization agent.

Abstract: A method of preparing an implantable biomaterial film includes inputting a combination of a polymer and a neuro-regenerative agent or an immunosuppressive agent into an extruder. The method includes melting the polymer within the extruder. The method also includes extruding the combined polymer and the neuro-regenerative agent or the immunosuppressive agent to form the implantable biomaterial film.

Abstract: Compositions and methods for delivering vitamin D to a subject. In one embodiment the invention provides a transdermal patch for the transdermal administration of vitamin D comprising: (a) a backing layer that serves as the outer surface of the patch during use; (b) an adhesive drug reservoir layer for affixing the patch to skin; and (c) a release liner, which upon removal exposes the adhesive drug reservoir layer. The adhesive drug reservoir layer can include vitamin D, a polymeric adhesive, an organic solvent, and a permeation enhancer.

Abstract: A substrate (12) for delivering a biologically active substance. the substrate (12) comprising: a cross-linked silicone matrix formed by cross-linking a silicone polymer using at least one crosslinking agent comprising a tetraalkoxysilane, the cross-linked silicone matrix defining a plurality of domains, and a composition contained within the domains of the cross-linked silicone matrix, wherein the composition comprises: at least one monomeric glycol and at least one biologically active substance.

Abstract: A method for the production of a topical ophthalmic preparation useful as a tear substitute and agent for the treatment of the computer vision syndrome and the related product are disclosed. In addition to the water-soluble ingredients typical of aqueous eye drops or gels, the preparation also contains a stable micellar solution (or microemulsion) of lutein with vitamin E TPGS.

Abstract: A combination of active ingredients of plant origin or synthetic analogues or extracts of plant origin containing cinnamaldheyde and eugenol or derivatives thereof, useful as antimycotic for both human and veterinary therapeutic use, mainly against fungal infections caused by Candida. Compositions containing the combination for topical or systemic administration are also described.

Abstract: The disclosure features methods of treating a subject with acne, enlarged pores, hidradenitis, seborrhea, sebaceous hyperplasia, seborrheic dermatitis, sebaceous adenoma, sebaceous carcinoma, sebaceous cyst, wrinkles, or oily skin suppurativa by administration of a dexmecamylamine substantially free of exo-R-mecamylamine, or a pharmaceutically acceptable salt thereof to the subject.

Abstract: Disclosed are pharmaceutical compositions of ketamine and methods of their use in treatment, such as in ketamine-assisted psychotherapy (KAP), including both single KAP sessions and KAP treatment regimes, to treat patients with behavioural addictions, such as gambling disorder, gaming disorder, compulsive sexual behaviour disorder, and binge eating disorder, among others.

Abstract: A ready-to-administer epinephrine composition having between about 0.005 and about 0.07 mg/mL epinephrine, at least about 0.9 wt % sodium chloride; between about 1 and about 50 ug/mL ethylenediaminetetraacetic acid; 0.005 wt % or less sodium metabisulfite, and water. Also included are systems having the composition contained in a container.

Abstract: Disclosed herein are methods of treating subjects suffering from estrogen receptor positive cancer of the brain by administering a selective estrogen receptor degrader (SERM). Also disclosed are methods of treating a cancer that is resistant to an estrogen receptor modulator by administering a SERM.

Abstract: A composition for preventing, alleviating or treating nontuberculous mycobacteria (NTM) infectious diseases, contains clomiphene citrate as an active ingredient. The nontuberculous mycobacteria (NTM) are Mycobacterium abscessus (M. abscessus), Mycobacterium avium (M. avium) or Mycobacterium intracellulare (M. intracellulare). The clomiphene citrate inhibits the in-vitro growth of a wild-type strain, a clinical isolate or a clarithromycin-resistant strain of M. abscessus.

Abstract: Disclosed herein are methods of treating neurological or psychiatric diseases or disorders, such as nicotine addiction, using a combination of bupropion and dextromethorphan. Related compositions and dosage forms are also described.

Abstract: The present invention provides an aqueous ophthalmic solution comprising an effective amount of ketorolac which comprises carboxymethyl cellulose in an aqueous solution wherein said concentration of carboxymethyl cellulose is selected to provide an increased absorption of ketorolac in the eye of a patient that is at least 130% greater than the absorption of a comparative aqueous ketorolac ophthalmic solution having the same concentration of ketorolac.

Abstract: Provided is a composition for inhibiting anti-cancer drug resistance comprising a compound represented by Chemical Formula 1 below as an active ingredient: (wherein, R1 and R2 are each independently hydrogen, substitutable linear or branched C1-C12 alkyl, substitutable C3-C12 cycloalkyl, or substitutable C6-C18 aryl, R3 is carboxyl, hydroxyl, or acetyl, and the substitution is performed by oxygen, nitrogen, sulfur, linear or branched C1-C6 alkyl, C6-C20 aryl, halogen, or a combination thereof).

Abstract: This disclosure provides methods of treating medical disorders, and more particularly methods for treating one or more symptoms of Kabuki Syndrome.

Abstract: Disclosed herein are compositions and methods for treating overactive bladder. In some embodiments, the composition comprises an effective amount of micronized solabegron or a pharmaceutically acceptable salt or a derivative thereof. In some embodiments the micronized solabegron particles have a particle size of about 0.1 micron to 30 microns. In some embodiments, the administration of the pharmaceutical composition is twice daily.

Abstract: Methods of treating psoriasis with sustained release compression coated tablet dosage forms comprising certain MHF prodrugs are provided.

Abstract: The present disclosure relates to utilizing the N6-methyllysine for reducing fat percentage in an organ or tissue or for treating obesity, obesity-related diseases or cancers. More specifically, the present invention relates to the method using N?-Methyl-L-lysine or N?-Methyl-L-lysine producing bacteria or N?-Methyl-L-lysine/l-lysine mixture or N?-Methyl-L-lysine/probiotics mixture to treat obesity, obesity-related diseases or cancers.

Abstract: The present disclosure provides for treating lysosomal storage disorders (LSDs) comprising administering acetyl-leucine or a pharmaceutically acceptable salt thereof.

Abstract: A method for activating or enhancing expression of sirtuins or Klotho, including administering S-1-propenylcysteine or a salt thereof to an animal in need thereof. A method for increasing NAD+, including administering S-1-propenylcysteine or a salt thereof to an animal in need thereof. A method for suppressing senescent cells, including administering S-1-propenylcysteine or a salt thereof to an animal in need thereof.

Abstract: A pharmaceutical composition for treating hyperlipidemia and a preparation method therefor are provided. The pharmaceutical composition contains chlorogenic acid, vitamins, pharmaceutically acceptable excipients and optional microelements. The pharmaceutical composition for treating hyperlipidemia reduce can serum total cholesterol and serum triglyceride, and increase the content of high-density lipoproteins.

Abstract: This present disclosure relates to a method of stimulating an immune response using compounds that activate protein kinase C (PKC), including for treatment of a cancer, a precancerous lesion, a benign tumor, or a wound.

Abstract: The present disclosure generally relates to systems and methods for treating vitiligo. In one set of embodiments, the present disclosure comprises a composition comprising ethyl pyruvate. The composition may be formulated for application to the skin of a subject, for instance, as a gel, lotion, cream, ointment, soap, or stick. In some cases, the composition may comprise a lecithin, such as phosphatidylcholine. In certain embodiments. the lecithin is present as a liquid crystal, and/or in liposomes, micelles, or other vesicles. Other aspects of the present disclosure are generally directed to methods of making or using such compositions, methods of promoting such compositions, kits including such compositions, or the like.

Abstract: Compositions for inducing and maintaining a state of flow in a subject include optically pure S-beta-hydroxybutyrate or non-racemic mixtures enriched with the S-enantiomer. The S-beta-hydroxybutyrate enantiomer modulates the effect of ketone bodies in the subject and controls the rate at which ketosis is achieved. Beta-hydroxybutyric acid is more rapidly absorbed and utilized by the body than salts or esters, enhances taste, and reduces the need to include citric acid or other edible acids. Beta-hydroxybutyrate salts are more slowly absorbed and utilized by the body and can provide one or more electrolytes. Compositions for controlling ketone body level in a subject may contain a dietetically or pharmaceutically acceptable carrier and optically pure S-beta-hydroxybutyrate or non-racemic mixture enriched with S-beta-hydroxybutyrate, wherein the compositions contain from about 50.5% to 100% by enantiomeric equivalents of S-beta-hydroxybutyrate and from about 49.

Abstract: The present invention relates to a method of treating herpes zoster (shingles), such as in the acute eruptive phase, comprising topically administering tetracaine base (or a pharmaceutically acceptable salt thereof) to a patient in need of such treatment.

Abstract: The present invention relates to a method of treating herpes zoster (shingles), such as in the acute eruptive phase, or deactivating varicella zoster virus (the virus that canses herpes zoster), such as an in a patient suffering from herpes zoster, comprising topically administering tetracaine base (or a pharmaceutically acceptable salt thereof) to a patient in need of such treatment.

Abstract: Embodiments of the invention relate to the use of a melatonin agonist in the treatment of free running circadian rhythms in patients, including light perception impaired patients, e.g., blind patients, and to methods of measuring circadian rhythm.

Abstract: The present invention relates to a composition for inhibiting skin pigmentation through enhanced autophagy activity, comprising procyanidin A2 and quercetin as active ingredients. The combination of procyanidin A2 and quercetin compounds not only inhibits tyrosinase but also increases autophagy activity, thus showing remarkable effectiveness in inhibiting melanin synthesis. Therefore, this composition can be advantageously used in various materials, including food products, cosmetic compositions, and pharmaceutical compositions, associated with skin pigmentation.

Abstract: The present invention relates to a novel compound that inhibits the mTOR signaling pathway, a method for preparing same, and a pharmaceutical composition comprising same as an active ingredient. The compound of the present invention was found to inhibit mTORC1 and mTORC2 activities, activate autophagy, and alleviate a series of disease symptoms associated with Alzheimer's-type dementia in dementia model animals, and thus can be effectively used as a pharmaceutical composition capable of preventing or treating nervous system diseases comprising neurodegenerative diseases and mTORopathy.